| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Pathological stage and grade have limited ability to predict the outcomes of superficial urothelial bladder carcinoma at initial transurethral resection. We are seeking a novel marker to distinguish high-risk cases to choose adequate treatment as soon as possible. A transcription factor, ATBF1 should be normally localized in the nucleus, but it has been observed in the cytoplasm of several cancers. When we distinguished two groups according to positive nuclear staining of ATBF1, we found a significant difference in overall survival and intravesical recurrence-free survival in ATBF1-positive compared with ATBF1-negative cases. Cleavage of ATBF1 increases cytoplasmic fragments of ATBF1 and reduces the amount of ATBF1 in the nucleus. Alteration of subcellular localization due to fragmentation of ATBF1 is related to the malignant character of urothelial carcinoma.
|
